PT  - JOURNAL ARTICLE
AU  - Dimcheff, Derek E.
AU  - Valesano, Andrew L.
AU  - Rumfelt, Kalee E.
AU  - Fitzsimmons, William J.
AU  - Blair, Christopher
AU  - Mirabelli, Carmen
AU  - Petrie, Joshua G.
AU  - Martin, Emily T.
AU  - Bhambhani, Chandan
AU  - Tewari, Muneesh
AU  - Lauring, Adam S.
TI  - SARS-CoV-2 Total and Subgenomic RNA Viral Load in Hospitalized Patients
AID  - 10.1101/2021.02.25.21252493
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.25.21252493
4099  - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252493.short
4100  - http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252493.full
AB  - Understanding viral load in patients infected with SARS-CoV-2 is critical to epidemiology and infection control. Previous studies have demonstrated that SARS-CoV-2 RNA can be detected for many weeks after symptom onset. The clinical significance of this finding is unclear and, in most patients, likely does not represent active infection. There are, however, patients who shed infectious virus for weeks. Detection of subgenomic RNA transcripts expressed by SARS-CoV-2 has been proposed to represent productive infection and may be a tractable marker for monitoring infectivity. Here, we use RT-PCR to quantify total and subgenomic nucleocapsid (N) and envelope (E) transcripts in 190 SARS-CoV-2 positive samples collected on hospital admission. We relate these findings to duration of symptoms. We find that all transcripts decline at the same rate; however, subgenomic E becomes undetectable before other transcripts. In Kaplan-Meier analysis the median duration of symptoms to a negative test is 14 days for sgE and 25 days for sgN. There is a linear decline in subgenomic RNA compared to total RNA suggesting subgenomic transcript copy number is highly dependent on copy number of total transcripts. The mean difference between total N and subgenomic N is 16-fold (4.0 cycles) and the mean difference between total E and sub-genomic E is 137-fold (7.1 cycles). This relationship is constant over duration of symptoms allowing prediction of subgenomic copy number from total copy number. Although Subgenomic E is undetectable at a time that may more closely reflect the duration of infectivity, its utility in determining active infection may be no more useful than a copy number threshold determined for total transcripts.Competing Interest StatementASL reports receiving consulting fees from Sanofi on antiviral drugs and is a paid member of a steering committee for a clinical trial of baloxavir (Roche).Funding StatementThis work was supported by a University of Michigan COVID-19 Response Innovation Grant (to ASL), K01AI141579 (to JGP) and CDC U01 IP000974 (to ETM)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Michigan Institutional Review Board, #HUM00105491All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data are presented in the manuscript.